Trial Profile
A phase II Human Challenge Trial (HCT) of VXA-CoV2-1
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2023
Price :
$35
*
At a glance
- Drugs VXA CoV2-1 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 15 Mar 2023 According to a Vaxart media release, company is postponing further COVID-19 clinical trials, including this Omicron Human Challenge Trial in the UK.
- 08 Aug 2022 According to a Vaxart media release, the company expects to initiate this study in the UK starting in the 2H 2023.
- 13 Jul 2022 New trial record